GENEVA--(BUSINESS WIRE)--Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), informs its shareholders that the 2023 Annual General Meeting will be held on Wednesday June 14, 2023 at 3.00 pm at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates, Geneva, Switzerland.
The notice for the meeting, including the agenda of the day as well as the motions put to the vote, has been published today in the Feuille Officielle Suisse du Commerce.
The documents and preliminary information concerning this meeting are being made available to the shareholders and can be consulted on the website of the Company: www.geneuro.com, under the section Investors / Documentation / Shareholders meeting.
It is also possible to consult the documents at the Company’s headquarters, chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates. Each shareholder has the right to request a hard copy of those documents.
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com